Deep Brain Stimulation for Refractory Alcoholism
Pilot Study of Deep Brain Stimulation (DBS) for Refractory Alcoholism
2 other identifiers
interventional
N/A
0 countries
N/A
Brief Summary
Background: \- Current treatments for alcoholism have limited success. More than half of people with alcoholism return to uncontrolled drinking even after treatment or self-help programs. One possible treatment is the use of deep brain stimulation (DBS). DBS studies of the ventral capsule/ventral striatum, a region of the brain, reduced cravings for alcohol in a small group of alcoholics. DBS is approved for treating other disorders, such as Parkinson s disease, but not for treating alcoholism. Researchers want to study whether DBS can be used to treat chronic alcoholism. Objectives: \- To see if deep brain stimulation is helpful and safe for people who have chronic alcoholism. Eligibility:
- Individuals between 21 and 60 years of age who have been diagnosed with chronic alcoholism.
- Participants must have tried for more than 10 years to stop drinking alcohol, and have failed multiple treatment and self-help programs. They may not have any other current substance abuse or dependence problem (except alcohol and nicotine). Design:
- Participants will start the study by entering a separate alcohol detoxification study at the National Institutes of Health. They will be monitored during this study with blood tests and brain scans.
- Participants will have 2 weeks of baseline tests. They will include physical exams and blood and urine tests. They will also include tests of thinking and memory, and questions about current moods.
- Participants will have surgery to insert the DBS device. Electrodes will be placed in the brain and a battery pack will be placed in the chest. Participants will recover from the surgery and continue the alcohol detoxification program.
- About 4 weeks after surgery, participants will be separated into two groups. For one group, the DBS device will be turned on with electrical stimulation and participants will be monitored for an additional two weeks in the hospital to find the right setting for the device. For the second group, participants will receive mock stimulation, but no real electrical DBS, and will also be monitored for an additional two weeks in the hospital.
- Participants will return home for 24 weeks. During this time they will have frequent study visits to look at the DBS device. These visits will include questions about mood and memory, as well as imaging studies.
- All participants will return for an additional two week inpatient stay in the hospital. Those participant who had initially received mock stimulation will now have their devices turned on with real electrical stimulation and will be monitored for the two weeks to find the right setting for the device. Those participants who had initially received real stimulation will continue to receive stimulation while being monitored for the two weeks.
- Participants will return home for another 24. All participants at this point will have actual electrical DBS. Participants will continue to have frequent study visits for up to a year to look at the DBS device. These visits will also include questions about mood levels and alcohol cravings.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Nov 2012
Typical duration for phase_1
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 30, 2012
CompletedFirst Submitted
Initial submission to the registry
February 22, 2013
CompletedFirst Posted
Study publicly available on registry
February 26, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 13, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
November 13, 2015
CompletedDecember 17, 2019
November 13, 2015
3 years
February 22, 2013
December 14, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Test safety of DBS of the nucleus accumbens, ventral striatum and ventral capsule in patients with treatment-resistant alcoholism.
2 years
Interventions
Eligibility Criteria
You may qualify if:
- Enrolled in 05-AA-0121.
- Age 21-60 years at time of enrollment.
- Fulfills DSM-IV diagnostic criteria for alcohol dependence.
- Has no current DSM-IV substance dependence diagnoses except for alcoholism and nicotine dependence.
- Has demonstrated greater than 10 years of refractory symptoms of alcohol dependence.
- Has failed two or more detoxification and rehabilitation treatment programs (both inpatient and outpatient).
- Has failed two or more community and self-help programs.
- Has failed standard psychotherapeutic and pharmacological treatments.
- Is unable to remain sober for more than a 6-month period (excluding periods of incarceration, inpatient treatment programs, or in a closely supervised therapeutic community) in the last 5 years.
- Has serious psychological and/or psychosocial consequences of alcohol dependence.
- Has a stable living arrangement (e.g., living in proximity to people who will assist with monitoring subject s behavior, encouraging subjects to attend clinic visits, and providing contact information) that will provide reasonable assurance that they will participate in follow-up evaluations following DBS implantation.
- Is able to comprehend the consent form and provide informed consent.
- Is fluent in the English language.
- A physician outside of the intramural NIAAA program, who is an expert in the treatment of substance abuse, will review each candidate s coded records prior to enrollment. The purpose of this review is to assure that the candidate has severe, treatment resistant alcoholism (as defined by criteria 5-10).
You may not qualify if:
- Has medical problems requiring intensive medical or diagnostic management, including:
- a diagnosis of acute myocardial infarction or cardiac arrest within the previous 6 months
- history of a neurosurgical ablation procedure
- any medical contraindications to undergoing DBS surgery
- history of hemorrhagic stroke
- life expectancy of \<3 years
- Has abnormal coagulation lab studies, defined as INR \>1.4, abnormal PT/PTT.
- Has liver function tests \> 3 times the upper limit of normal (ULN).
- Has infection with the Human Immunodeficiency Virus (HIV), because of the potential for CNS involvement which might confound the analysis of study outcomes.
- Is participating in other clinical trials that would compromise the ability to determine the safety and efficacy of this study.
- Has a past or present diagnosis of schizophrenia, bipolar disease, or any psychotic disorder other than one determined to be substance induced; past or present diagnosis of dementia or any other disorder which has led to a clinically significant cognitive impairment.
- Has manifested behaviors such as violence which, in the investigator s judgment, could lead to non-compliance with study procedures.
- Is unable to undergo MR-imaging because of implanted pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or cochlear implants), shrapnel fragments, permanent eye liner or small metal fragments in the eye that welders and other metal workers may have, or if candidates are uncomfortable in small closed spaces (have claustrophobia), or cannot lie comfortably on their back for up to one hour
- Has known destruction and/or damage to the nucleus accumbens, ventral striatum and ventral capsule region as determined by MRI.
- Has documentation of an MRI abnormality indicative of a neurological condition that may jeopardize the subject s safety, the conduct of the study, or confound the subject s diagnosis or assessments.
- +5 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (3)
Baker KB, Kopell BH, Malone D, Horenstein C, Lowe M, Phillips MD, Rezai AR. Deep brain stimulation for obsessive-compulsive disorder: using functional magnetic resonance imaging and electrophysiological techniques: technical case report. Neurosurgery. 2007 Nov;61(5 Suppl 2):E367-8; discussion E368. doi: 10.1227/01.neu.0000303995.66902.36.
PMID: 18091226BACKGROUNDBauer R, Pohl S, Klosterkotter J, Kuhn J. [Deep brain stimulation in the context of addiction--a literature-based systematic evaluation]. Fortschr Neurol Psychiatr. 2008 Jul;76(7):396-401. doi: 10.1055/s-2008-1038217. German.
PMID: 18604773BACKGROUNDBewernick BH, Hurlemann R, Matusch A, Kayser S, Grubert C, Hadrysiewicz B, Axmacher N, Lemke M, Cooper-Mahkorn D, Cohen MX, Brockmann H, Lenartz D, Sturm V, Schlaepfer TE. Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Biol Psychiatry. 2010 Jan 15;67(2):110-6. doi: 10.1016/j.biopsych.2009.09.013.
PMID: 19914605BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Kareem A Zaghloul, M.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- NIH
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 22, 2013
First Posted
February 26, 2013
Study Start
November 30, 2012
Primary Completion
November 13, 2015
Study Completion
November 13, 2015
Last Updated
December 17, 2019
Record last verified: 2015-11-13